| Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development HM Jones, K Rowland‐Yeo CPT: pharmacometrics & systems pharmacology 2 (8), 1-12, 2013 | 600 | 2013 |
| Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective HM Jones, Y Chen, C Gibson, T Heimbach, N Parrott, SA Peters, ... Clinical Pharmacology & Therapeutics 97 (3), 247-262, 2015 | 459 | 2015 |
| A novel strategy for physiologically based predictions of human pharmacokinetics HM Jones, N Parrott, K Jorga, T Lavé Clinical pharmacokinetics 45, 511-542, 2006 | 392 | 2006 |
| Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches NA Hosea, WT Collard, S Cole, TS Maurer, RX Fang, H Jones, SM Kakar, ... The Journal of Clinical Pharmacology 49 (5), 513-533, 2009 | 304 | 2009 |
| Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data HM Jones, HA Barton, Y Lai, Y Bi, E Kimoto, S Kempshall, SC Tate, ... Drug Metabolism and Disposition 40 (5), 1007-1017, 2012 | 263 | 2012 |
| Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit PV Fish, P Filippakopoulos, G Bish, PE Brennan, ME Bunnage, AS Cook, ... Journal of medicinal chemistry 55 (22), 9831-9837, 2012 | 252 | 2012 |
| Modelling and PBPK simulation in drug discovery HM Jones, IB Gardner, KJ Watson The AAPS journal 11, 155-166, 2009 | 220 | 2009 |
| PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based … P Poulin, RDO Jones, HM Jones, CR Gibson, M Rowland, JY Chien, ... Journal of pharmaceutical sciences 100 (10), 4127-4157, 2011 | 214 | 2011 |
| Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations HM Jones, JB Houston Drug Metabolism and Disposition 32 (9), 973-982, 2004 | 214 | 2004 |
| PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance BJ Ring, JY Chien, KK Adkison, HM Jones, M Rowland, RD Jones, ... Journal of pharmaceutical sciences 100 (10), 4090-4110, 2011 | 198 | 2011 |
| Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling HM Jones, N Parrott, G Ohlenbusch, T Lavé Clinical pharmacokinetics 45, 1213-1226, 2006 | 161 | 2006 |
| The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition A Rakhit, MP Pantze, S Fettner, HM Jones, JE Charoin, M Riek, BL Lum, ... European journal of clinical pharmacology 64, 31-41, 2008 | 133 | 2008 |
| PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution R Do Jones, HM Jones, M Rowland, CR Gibson, JWT Yates, JY Chien, ... Journal of pharmaceutical sciences 100 (10), 4074-4089, 2011 | 132 | 2011 |
| Dose selection based on physiologically based pharmacokinetic (PBPK) approaches HM Jones, K Mayawala, P Poulin The AAPS journal 15 (2), 377-387, 2013 | 118 | 2013 |
| Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling HM Jones, IB Gardner, WT Collard, PJ Stanley, P Oxley, NA Hosea, ... Clinical pharmacokinetics 50, 331-347, 2011 | 116 | 2011 |
| Application of PBPK modelling in drug discovery and development at Pfizer HM Jones, M Dickins, K Youdim, JR Gosset, NJ Attkins, TL Hay, IK Gurrell, ... Xenobiotica 42 (1), 94-106, 2012 | 113 | 2012 |
| Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man N Parrott, H Jones, N Paquereau, T Lavé Basic & clinical pharmacology & toxicology 96 (3), 193-199, 2005 | 105 | 2005 |
| Maraviroc: in vitro assessment of drug–drug interaction potential R Hyland, M Dickins, C Collins, H Jones, B Jones British journal of clinical pharmacology 66 (4), 498-507, 2008 | 103 | 2008 |
| Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies LB Avery, M Wang, MS Kavosi, A Joyce, JC Kurz, YY Fan, ME Dowty, ... MAbs 8 (6), 1064-1078, 2016 | 82 | 2016 |
| Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model S Yamazaki, J Skaptason, D Romero, S Vekich, HM Jones, W Tan, ... Drug metabolism and disposition 39 (3), 383-393, 2011 | 75 | 2011 |
